Evidence map›Paper›PMID 39509206›Full record

ArticleThe Biochemical journal2024

Sequence variation in the active site of mobile colistin resistance proteins is evolutionarily accommodated through inter-domain interactions.

Avani Joshi, Nishad Matange

Abstract read
In one paragraph

Article in The Biochemical journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Avani JoshiDepartment of Biology, Indian Institute of Science Education and Research, Pashan, Pune, India.
Nishad MatangeDepartment of Biology, Indian Institute of Science Education and Research, Pashan, Pune, India.ORCID 0000-0002-2947-3931

Funding

DBT-Wellcome Trust India Alliance IA/I/20/2/505181Wellcome Trust
6 · The paper itself

Abstract

Sequence variation among homologous proteins can shed light on their function and ancestry. In this study, we analyze variation at catalytic residues among MCR (mobile colistin resistance) proteins, which confer resistance to the last resort antibiotic, colistin, in gram-negative bacteria. We show that not all naturally occurring variants at a lipid A-binding residue, Ser284, are tolerated in MCR-1. In particular, the substitution of Ser284 with Asp, found naturally in MCR-5, resulted in diminished colistin resistance. Using phylogenetic analyses and structure predictions we trace back variation at this site among MCRs to their ancestors, i.e. EptA phosphoethanolamine transferases that are encoded by diverse bacterial genomes. Mutational studies and AlphaFold-based structural modeling revealed that the functional importance of position 284 varies between phylogenetically distant MCRs, i.e. MCR-1 and MCR-5. Despite a high degree of similarity among their catalytic domains, inter-domain interactions were not conserved between MCR-1 and MCR-5 due to their different ancestries, providing a mechanistic basis behind the different phenotypes of similar mutations at position 284. Our study thus uncovers subtle differences in the organization of domains among MCR proteins that can lead to substantial differences in their catalytic properties and mutational tolerances.

Indexed as

Catalytic DomainColistinDrug Resistance, BacterialEvolution, MolecularPhylogenyAmino Acid SequenceAnti-Bacterial AgentsBacterial ProteinsEscherichia coliEscherichia coli ProteinsModels, MolecularAnti-Bacterial AgentsBacterial ProteinsColistinEscherichia coli ProteinsMCR-1 protein, E coliAlphaFold modelingantimicrobial resistancecolistinMCRnatural sequence variation

Identifiers

PMID39509206
PMCPMC7617329

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.